These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33362770)

  • 1. Targeting IL-1β in the Treatment of Atherosclerosis.
    Mai W; Liao Y
    Front Immunol; 2020; 11():589654. PubMed ID: 33362770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A perspective on targeting inflammation and cytokine actions in atherosclerosis.
    Chan YH; Ramji DP
    Future Med Chem; 2020 Apr; 12(7):613-626. PubMed ID: 32175772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherosclerosis: perspectives of anti-inflammatory therapy.
    Nasonov EL; Popkova TV
    Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.
    Khan R; Rheaume E; Tardif JC
    Curr Atheroscler Rep; 2018 Sep; 20(11):53. PubMed ID: 30219977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
    Ait-Oufella H; Libby P; Tedgui A
    Arterioscler Thromb Vasc Biol; 2019 Aug; 39(8):1510-1519. PubMed ID: 31294625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
    Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
    Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
    N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
    Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
    J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
    Grebe A; Hoss F; Latz E
    Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.
    Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ
    Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
    Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
    J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis.
    Vromman A; Ruvkun V; Shvartz E; Wojtkiewicz G; Santos Masson G; Tesmenitsky Y; Folco E; Gram H; Nahrendorf M; Swirski FK; Sukhova GK; Libby P
    Eur Heart J; 2019 Aug; 40(30):2482-2491. PubMed ID: 30698710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice.
    Guler R; Parihar SP; Spohn G; Johansen P; Brombacher F; Bachmann MF
    Vaccine; 2011 Feb; 29(6):1339-46. PubMed ID: 21093494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week.
    Ridker PM
    J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for cardiovascular disease.
    Lutgens E; Atzler D; Döring Y; Duchene J; Steffens S; Weber C
    Eur Heart J; 2019 Dec; 40(48):3937-3946. PubMed ID: 31121017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
    Ridker PM; MacFadyen JG; Thuren T; Libby P
    Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.